Possibilities for the use of tofacitinib in patients with COVID-19
Open Access
- 28 October 2020
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 4S,p. 35-38
- https://doi.org/10.37489/2588-0519-2020-s4-35-38
Abstract
No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected. Taken into account possible complications of the use of tofacitinib (infections, lymphopenia, venous thromboembolism), routine use of tofacitinib cannot be recommended unless within clinical trials under supervision of qualified healthcare professionals.Keywords
This publication has 12 references indexed in Scilit:
- Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysisRheumatology, 2020
- The Promise and Peril of Natural Killer Cell Therapies in Pulmonary InfectionImmunity, 2020
- How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinionAutoimmunity Reviews, 2020
- Going Viral: Management of IBD in the Era of the COVID-19 PandemicDigestive Diseases and Sciences, 2020
- Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on TofacitinibInflammatory Bowel Diseases, 2020
- British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicGut, 2020
- The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseJournal for ImmunoTherapy of Cancer, 2019
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programmeAlimentary Pharmacology & Therapeutics, 2019
- Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world settingRMD Open, 2019
- Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospectsRheumatology Science and Practice, 2019